Intervention not reported
Grade 3/4 cardiotoxicity · patients with newly diagnosed AML
The intervention showed no clear difference in grade 3/4 cardiotoxicity (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life not reported · patients with newly diagnosed AML
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Mortality at 2 years · patients with newly diagnosed AML
The intervention showed no clear difference in mortality at 2 years (high certainty).
1 finding from 1 review
Intervention not reported
Mortality/relapse at 2 years · patients with newly diagnosed AML
The intervention showed no clear difference in mortality/relapse at 2 years (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · individuals with HL
1 finding from 1 review
Intervention not reported
PFS: relapse or death · individuals with HL
The intervention probably leads to higher PFS: relapse or death (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · individuals with HL
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · individuals with HL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Treatment related mortality · individuals with HL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (12 months) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor showed no clear difference in mortality (12 months) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to engraftment · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of transplanted participants · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful stem cell collection · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor leads to higher successful stem cell collection compared with placebo (high certainty).
1 finding from 1 review
Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).
1 finding from 1 review
Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review